138 related articles for article (PubMed ID: 23412117)
1. [A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
Kim H; Shoji S; Usui Y; Nagata Y; Terachi T; Uchida T
Hinyokika Kiyo; 2013 Jan; 59(1):7-10. PubMed ID: 23412117
[TBL] [Abstract][Full Text] [Related]
2. [Brain metastasis which appeared during complete response of lung metastatic lesion by sunitinib treatment in a patient with renal cell carcinoma].
Morizawa Y; Momose H; Toyoshima Y; Takada S; Fujimoto K; Oyama N
Hinyokika Kiyo; 2013 Dec; 59(12):791-3. PubMed ID: 24419011
[TBL] [Abstract][Full Text] [Related]
3. [A case of interstitial lung disease due to sunitinib].
Sekiguchi Z; Takizawa A; Takeshima T; Tsuchiya F; Iwasaki A; Matsuyama S; Hirooka N
Hinyokika Kiyo; 2012 Sep; 58(9):481-5. PubMed ID: 23070386
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Yoshinaga A; Kamata S
Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
[TBL] [Abstract][Full Text] [Related]
5. [PATHOLOGICAL COMPLETE RESPONSE WITH EVEROLIMUS FOR MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA RESISTANT TO SUNITINIB].
Namura K; Otake S; Sawada T; Fujikawa A; Ota J; Moriyama M
Nihon Hinyokika Gakkai Zasshi; 2015 Jan; 106(1):30-4. PubMed ID: 26399128
[TBL] [Abstract][Full Text] [Related]
6. [Metastasis to the Tongue from Renal Cell Carcinoma 10 Years after Nephrectomy : A Case Report].
Wang C; Takeda K; Shiba M; Takayama H; Munakata S
Hinyokika Kiyo; 2016 Aug; 62(8):407-10. PubMed ID: 27624106
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases.
Makino K; Yoda K; Tomoishi J; Kume H
BMC Res Notes; 2014 Dec; 7():872. PubMed ID: 25471941
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up.
Zhang CJ; Zhao PJ; Li XS; Zhao J; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; He ZS; Jin J; Zhou LQ
Chin Med J (Engl); 2013; 126(15):2826-9. PubMed ID: 23924450
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma.
Ohzeki T; Fukasawa S; Komaru A; Namekawa T; Sato Y; Takagi K; Kobayashi M; Uemura H; Ichikawa T; Ueda T
Int J Urol; 2014 Oct; 21(10):1065-8. PubMed ID: 24930736
[TBL] [Abstract][Full Text] [Related]
11. Renal cell carcinoma: complete response.
Calvo OF; Vázquez DD; López MR; Aparicio LM
Anticancer Drugs; 2010 Jan; 21 Suppl 1():S17-8. PubMed ID: 20110782
[TBL] [Abstract][Full Text] [Related]
12. [Pre- surgical therapy with sunitinib for adrenal metastasis from renal cell carcinoma : a case report].
Inoue T; Murota T; Masuda T; Nishida T; Kawakita S; Kinoshita H; Matsuda T
Hinyokika Kiyo; 2013 Sep; 59(9):573-7. PubMed ID: 24113755
[TBL] [Abstract][Full Text] [Related]
13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
14. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Kahl C; Hilgendorf I; Freund M; Casper J
Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
[No Abstract] [Full Text] [Related]
15. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
16. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis.
Buti S; Donini M; Lazzarelli S; Passalacqua R
Acta Biomed; 2012 Aug; 83(2):88-94. PubMed ID: 23393915
[TBL] [Abstract][Full Text] [Related]
17. How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.
Bracarda S; Negrier S; Casper J; Porta C; Schmidinger M; Larkin J; Gross Goupil M; Escudier B
Expert Rev Anticancer Ther; 2017 Mar; 17(3):227-233. PubMed ID: 28044472
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and tolerability of a sunitinib 3-week administration schedule in metastatic renal cell carcinoma patients: report of three cases.
Neri B; Vannini A; Tassi R; Brugia M; Rangan S; Rediti M; Cerullo C
Oncol Res; 2012; 20(5-6):259-64. PubMed ID: 23581233
[TBL] [Abstract][Full Text] [Related]
19. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
Harshman L; Srinivas S
Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
[No Abstract] [Full Text] [Related]
20. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
